Skip to main content
Premium Trial:

Request an Annual Quote

Metrion Biosciences Closes £2.7M in Equity Financing

NEW YORK – Drug discovery firm Metrion Biosciences said Tuesday that it has closed on £2.7 million ($3.7 million) in new equity financing, including £2.25 million from lead investor Gresham House Ventures.

Cambridge, UK-based Metrion said it will use the funding to expand its laboratories, invest in specialty equipment, develop its cell line library, add GLP cardiac safety services, and expand its business to the US.

The firm specializes in ion channel contract research and drug discovery, and offers a panel of in vitro cardiac ion channel safety assays; translational native cell and phenotypic assays for neurological and cardiotoxicity testing; and a range of other ion channel screening services.

"This new investment, led by Gresham House Ventures, is a key part of Metrion's strategic development, enabling the company to expand its laboratories in Cambridge, UK, provide enhanced services to customers, and invest more extensively in US business development," Keith McCullagh, chairman of Metrion Biosciences, said in a statement.

In connection with the financing, Maya Ward, associate director at Gresham House Ventures, has been appointed to Metrion's board of directors.

The Scan

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.

Neurological Outcomes Linked to Innate Immune Features After Cardiac Arrest

Researchers reporting in Med dig into immune features found a few hours after cardiac arrest that correspond with neurological outcomes.

Mouse Study Finds Circadian Rhythm-Related Gene Expression Changes Linked to Sleep Apnea

A paper in PLOS Biology reveals tissue-specific circadian rhythm and gene expression patterns in an intermittent hypoxia-based mouse model of obstructive sleep apnea.

Polygenic Risk Score to Predict Preeclampsia, Gestational Hypertension in Pregnant Women

Researchers in Nature Medicine provide new mechanistic insights into the development of hypertensive disorders of pregnancy, which may help develop therapeutics.